- Title: Subtitle
- Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
- Creators
- Nizar Jacques Bahlis - University of CalgaryMichael H. Tomasson - University of IowaMohamad Mohty - Hôpital Saint-AntoineRuben Niesvizky - NewYork–Presbyterian HospitalAjay K. Nooka - Emory UniversitySalomon Manier - 6CHU de Lille, Lille, FranceChristopher Maisel - Baylor University Medical CenterYogesh Jethava - Pediatric Dermatology Research AllianceJoaquin Martinez-Lopez - Hospital Universitario 12 De OctubreH Miles Prince - Epworth HospitalBertrand Arnulf - Hôpital Saint-LouisPaula Rodriguez OteroGuenther Koehne - New England Baptist HospitalCyrille Touzeau - Centre Hospitalier Universitaire de NantesNoopur Raje - Massachusetts General HospitalShinsuke Iida - Nagoya City UniversityMarc-Steffen Raab - University Hospital HeidelbergEric Leip - Pfizer (United Kingdom)Sharon Sullivan - Pfizer (United Kingdom)Umberto Conte - 20Pfizer Inc, New York, NYAndrea Viqueira - Pfizer (United Kingdom)Alexander M Lesokhin - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.391-393
- DOI
- 10.1182/blood-2022-162440
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984363282102771
Abstract
Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
Blood, Vol.140(Supplement 1), pp.391-393
11/15/2022
DOI: 10.1182/blood-2022-162440
Details
Metrics
231 Record Views